Further Studies of Red Cell Destruction in Rats Bearing a Transplantable Tumour by Simpson, Shirley M. & Belcher, E. H.
361
FURTHER STUDIES OF RED CELL DESTRUCTION IN RATS
BEARING A TRANSPLANTABLE TUMOUR
SHIRLEY M. SIMPSON* AND E. H. BELCHER
From the Postgraduate Medical School, London, W.12
Received for publication April 4, 1962
IN a previous communication (Belcher and Simpson, 1960), investigations of
the nature of an acute haemolytic anaemia developing in rats of the August
strain bearing the transplantable adenocarcinoma R2426, were described. Studies
ofred cell survival using 51Cr and 59Fe revealed that the haemolytic episode which
developed 10-15 days after implantation of the tumour was a true haemolytic
anaemia resulting from extensive red cell destruction in the tumour-bearing
animals. Cells were destroyed randomly without regard to age, the sites of red
cell destruction being primarily the spleen and liver, while destruction in the
tumour itself was negligible.
It was found that a similar haemolytic episode could be induced in normal
animals by transfusion of blood from tumour-bearing donors. The rapidity of
onset of the haemolytic episode was related to the amount of blood transfused
and to the time after implantation at which the blood was taken from the tumour-
bearing donor.
After the initial haemolytic episode induced by implant or transfusion, it was
found to be impossible to induce a second episode in the same animal. Further-
more, red cells from a tumour-bearing donor which had suffered a haemolytic
episode showed near-normal survival when transfused to normal recipients,
although they provoked a haemolytic episode in the recipient.
It was found that the haemolytic episode could be induced by transfusions of
minute quantities of blood, that the concentration ofthe haemolytic agent in the
blood of the tumour-bearing rat increased continuously from implantation up to
to onset of the haemolytic episode and that the time required for the haemolytic
episode to develop in normal rats transfused with blood from tumour-bearing
donors was related to the amount of blood transfused. These observations led
to the tentative conclusion that the responsible agent was some factor, possibly
viral in nature, which multiplied within the host. The present paper describes
experiments performed to establish whether or not the factor inducing the haemo-
lytic episode is in fact of an infectious nature and, ifthis were the case, to deter-
mine its specificity with regard to tumour and host, its site of multiplication
within the host and its ability to provoke an antibody reaction by the host.
MATERIALS AND METHODS
Rats ofthe pure bred August strain 100-200 g. in weight were usedthroughout.
They were maintained on Medical Research Council Diet No. 41 and water ad
libitum.
* Present address: Strong Memorial Hospital, Rochestes 20, N.Y,SHIRLEY M. SIMPSON AND E. H. BELCHER
The methods of transplantation of the tumour and measurement of blood
haemoglobin and the technique of studying red cell survival using red cells from
litter-mate donors labelled in vitro with 5'Cr have been previously described
(Belcher and Simpson, 1960). In studies ofthe concentration ofhaemolytic agent
in blood or tissue extract, 0 5 ml. amounts ofblood or tissue extract were injected
intravenously into pairs of normal rats and the time in days between injection
and the onset of a haemolytic episode in the recipients used as an index of the
amount of haemolytic agent in the injected preparation.
RESULTS
Passage of haemolytic agent through non-tumour-bearing animals
In order to establish whether or not the haemolytic disease developing in
tumour-bearing rats is of an infectious nature, it was passaged through a series of
non-tumour-bearing animals. The initial donor was a tumour-bearing male August
rat which experienced a haemolytic episode manifested in the usual manner by a
sharp fall in blood haemoglobin level 10 days after implantation of the tumour.
0 5 ml. of blood, taken from this rat 13 days after implantation while it was re-
covering from the haemolytic episode, was transfused intravenously into a normal
recipient which subsequently developed a similar haemolytic episode and was
used as a donor ofblood to a second normal recipient. This rat in turn developed
a haemolytic episode and was used as a donor to a further normal recipient. The
results ofthe first 7 ofsuch transfers are shown in Fig. 1. It will be seen that each
successive recipient developed a haemolytic episode following transfusion and
that the haemolytic factor did not appear to undergo any reduction in virulence.
Studies with tumour extracts
Extracts ofthe tumour R2426 were prepared in the following manner. Thirty
days after implantation, a tumour-bearing rat was exsanguinated and the tumour
was removed rapidly. It was cuit into small pieces which were washed with saline
in order to remove as much as possible of the blood which had remained in the
tumour after exsanguination. The tumour fragments were then homogenized in
a Waring blendor with two volumes of isotoniic saline buffered to pH 7 4. The
homogenate was centrifuged at 2,500 r.p.m. for 15 minutes. The residue was
discarded. The supernatant was collected and passed through a sterile Oxoid
filter (pore size 500 m,u) to remove bacterial contaminants. All ofthese operations
were performed at 5° C.
0.5 ml. portions of extracts prepared in this manner from a series of tumours
were injected intravenously into normal rats. Of 16 rats thus treated, 9 developed
a haemolytic episode following injection. In further experiments, well-washed
red cells from normal donors were incubated with an equal volume of tumour
extract for 2 hours at 370 C. The cells were then washed 3 times in 5 volumes of
saline and finally resuspended to their original volume in saline. 0 5 ml. aliquots
of the red cell suspension were injected into pairs of normal rats. Other animals
were given injections of 0 5 ml. of tumour extract alone, whilst further animals
were given 0*5 ml. ofblood taken from the donorbeforethe removal ofthe tumour.
Results of these experiments are shown in Table I. It is seen that normal cells
which have been incubated with tumour extract induced a haemolytic episode in
the recipient much more rapidly than did either tumour extract alone or blood
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FIG. 1.-Passage of haemolytic agent from tumour-bearing rat (1) through six normal rats by
successive transfusions ofblood.
TABLE I.-Delay in Onset of Haemolytic Episode in Rats Receiving Injections of
Blood from Tumour-bearing Donors, Tumour Extracts or Normal Red Cells
Incubated with Tumour Extracts.
Mean interval between injection and onset ofhaemolytic episode ~~~~~~~~A-
No. of Blood from tumour- Normal red cells incubated
experiment bearing donor Tumour extract alone with tumour extract
1 . 10 days No episode 7 days
2 . 6 days 4 days Died at 2 days as a result
ofacute anaemia
3 . 10 days No episode 8 days
4 . 10days 8 days 5 days
5 . 7 days 4 days 4 days
from the tumour-bearing donor. Contamination of the red cell suspension with
traces of tumour extract which failed to be removed by washing could not be
solely responsible for such an effect and the results suggest that the haemolytic
agent has been concentrated in some way by contact with the normal cells.- In
some instances, injection oftumour extract-failed to produce ahaemolytic episode
in the recipient, but injection ofred cells treated with tumourextract invariably
16§
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did so. It was found that the haemolytic activity oftumour extracts was destroyed
by heating to 60°C. for 30 minutes, but it was unchanged by passage through an
Oxoid filter (pore size 500 m,u) or by extraction with an equal volume ofpetroleum
ether.
Site of multiplication of haemnolytic agent in normal rats
Since the haemolytic agent may be passaged through iion-tumour-bearing
rats, it is presumably capable of multiplying in sites other than the tumour. In
order to determine the nature of these sites, the following experiment was per-
formed. A haemolytic episode was induced in a normal rat by injection of blood
from a tumour-bearing donor. The recipient was sacrificed during recovery from
the haemolytic episode and extracts of several tissues were made in the same
manner as described for the preparation oftumour extracts. These tissue extracts
were incubated for 2 hours at 370 C. with red cells and the treated red cells were
injected into pairs of normal recipients. The results, shown in Table II, suggest
TABLE II.-Delay in Onset of Haemolytic Episode in Rats Receiving Injections of
Red Cells Incubated with Tissue Extractsfrom Normal Rats Previously Injected
with Bloodfrom Tumour-bearing Donor.
Interval between
injection and onset
Tissue of haemolytic episode
Kidney. . . 5 days
Whole blood 4 days
Spleen . . 5 days
Liver . . 6 days
Muscle . . 5 days
Liver from normal rat No episode
that the haemolytic agent is present in a wide variety of tissues. Although care
was taken to free the tissues of contaminating blood before homogenization, it is
possible that traces of the blood persisted. However, the results cannot be ex-
plained simply on the grounds of contamination, since the concentration of
haemolytic factor in extracts of a variety of tissues tested appears nearly equal
to that in whole blood. Apparently the haemolytic agent is able to maintain itself
in several sites other than the tumour.
Specificity of the haemolytic agent
(a) Strain of rat.-The tumour R2426 from the August strain was implanted
into three other strains; a hooded black and white hybrid strain and two pure-
bred albino strains, the Marshall strain and a strain obtained from Dr. Thomlinson
of the M.R.C. Radiotherapeutic Research Unit. The tumour was found to grow
well in rats of the hybrid strain, but only for a limited period when implanted in
the other two strains. Red cell survival curves obtained using 5'Cr-labelled red
cells in tumour-bearing rats of these three strains were, however, found to be in-
distinguishable from those in normal animals.
It thus appears, that of the strains tested, only in the August strain is a
haemolytic episode induced by implantation of the tumour R2426. Two possible
explanations may be postulated for this observation. Either the haemolytic agent
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is not able to multiply in strains ofrat other than the August, or, ifit canmultiply
in other strains, then the red cells of rats of these strains are not susceptible to
haemolysis by the agent. In order to test which of these explanations is correct,
5'Cr-labelled red cells were transfused from a non-susceptible hybrid strain to the
susceptible August strain and vice versa, either the donor or recipient having been
implanted with the tumour. Haemolysis of the donor's cells could be observed
from 51Cr-survival measurements, whilst haemolysis of the recipient's cells could
be detected from measurements ofblood haemoglobin levels. The results ofthese
TABLE III.-Cross-transfusion Studies in Tumour-bearing Rats
Donor strain
August Hybrid
Normal Tumour-bearing Normal Tumour-bearing
Recipient ,~ , ,
strain D R D R D B D R
August. . Normal . No No Yes Yes No No No No
Tumour-bearing . Yes Yes Yes Yes Yes Yes Yes Yes
Hybrid. Normal . No No No No No No No No
Tumour-bearing . No No No No No No No No
D = Haemolysis in donor's cells.
R = Haemolysis in recipient's cells.
studies are summarized in Table III, from which the following observations may
be made:
1. Cells from tumour-bearing hybrid donors do not induce a haemolytic
episode in a normal August recipient.
2. Cells from a tumour-bearing August donor do not induce a haemo-
lytic episode in a normal hybrid recipient.
3. Cells from a normal hybrid donor are destroyed to the same extent
as cells ofthe host when transfused to a tumour-bearing August recipient.
Thus it appears that cells ofhybrid rats are susceptible to lysis by the haemo-
lytic agent. Consequently, the most probable explanation for the observations
that implantation of the tumour in a hybrid host fails to induce a haemolytic
episode is that the haemolytic agent is unable to maintain itself and to multiply
in the hybrid host.
(b) Type oftumour.-The effect on red cell survival ofthe implantation oftwo
other tumours of the August strain has been tested. These are the. mammary
adenocarcinoma D266 and the melanoma R428. The survival ofred cells of rats
implanted with the tumour R428 was found to be indistinguishable from normal.
However, August rats implanted with the tumour D266 were observed to develop
a haemolytic episode 12-14 days after implantation similar to that observed after
the implantationofR2426(Fig. 2). The haemolytic episodeinducedbythe tumour
D266 was less acute than that induced by R2426, some 40 per cent of the circu-
lating red cells surviving the episode.
It has been shown (Belcher and Simpson, 1960) that after a haemolytic episode
has been induced in a recipient animal by transfusion of blood from a donor
bearing the tumour R2426, it was impossible to induce a second episode in the
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recipient by further injection of blood or transplantation of the tumour. This
effect was used in order to test whether the anaemia provoked by implantation
of the tumour D266 was produced by a similar agent (Fig. 3). Blood taken from
a donor bearing the D266 tumour was transfused to a pair of normal recipients.
Fourteen days aftertransfusion, these rats experienced a mild haemolytic episode.
When their haemoglobin levels had returned to normal, the recipients were again
transfused, this time with blood from a donor bearing the R2426 tumour. Blood
from this donor was also transfused to two normal control animals. Six days later
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FIG. 2.-Blood haemoglobin levels and survival of 51Cr-labelled red cells in two " August " rats
implanted with tumour D266.
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FIG. 3.-Blood haemoglobin levels in " August " rats transfused with
bearing the tumour R2426.
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these controls experienced an acute haemolytic episode. The rats which pre-
viously had been transfused with blood from a donor bearing the D266 tumour,
however, did not experience a haemolytic episode during the period ofobservation
up to 3 weeks after transfusion. It appears that blood from a donor bearing the
tumour D266 is able, subsequently, to "protect" the recipient against the haemo-
lytic episode induced by blood from a R2426 donor. It may be inferred that the
agents producing the haemolytic episodes following the implantation of the
tumours R2426 and D266 have the same mode ofaction. It is perhaps significant
that both tumours are adenocarcinomata ofmammary origin.
Attentuation ofthefactor producing haenwlytic disease in tumour-bearing rats
Towards the end ofthese studies a change occurred in the haemolytic response
of August rats following implantation ofthe tumour R2426. In the last series of
rats implanted, the haemolytic episode was not observed until 20-21 days after
implantation, instead of after 10-15 days as previously found. As far as could
be judged, all other features of the haemolytic disease were unaltered. This de-
velopment suggests that the haemolytic agent had either become attenuated by
numerous passages through the host or that it had undergone some change in its
mode of action.
Production ofantibodies to the haemolytic agent
Inexperiments designed todetect the presenceofcirculatingantibodies against
the haemolytic agent, serum collected from tumour-bearing rats which had re-
covered from their haemolytic episodes was inactivated by heating to 560 C.
Dilutions oftumour extract were incubated with equal volumes ofthis serum for
1 hour at 370 C. The amount of active haemolytic agent remaining was then
estimated by injecting 0 5 ml. amounts ofthe mixture into pairs ofrecipient rats.
The results of two studies of this kind are summarized in Table IV. In the first
two experiments, the treated tumour extracts were injected alone. In the third,
they were adsorbed on to normal red cells, in the manner previously described,
TABLE IV.-Delay in Onset of Haemolytic Episode in Rats Receiving Injection.s of
Tumour Extracts Treated with Antisera
Experiment
No. Material injected
. 0-25 ml. tumour extract
0 5 ml. tumour extract + antiserum
1: 10 dilution tumour extract
1: 10 dilution tumour extract + antiserum
2 . 0-25 ml. tumour extract
0-5 ml. tumour extract + antiserum
3 . Red cells treated with tumour extract
Red cells treated with 1: 10 dilution tumour extract +
normal serum
Red cells treated with 1: 10 dilution tumour extract +
anti-serum
Red cells treated with 1: 100 dilution tumour extract
+ normal serum
Red cells treated with 1: 100 dilution tumour extract
+ anti-serum
Mean interval
between injection
and onset of
haemolytic episode
12 days
14 days
15 days
20 days
8 days
8 days
4 days
8 days
No episode
15 days
No episode
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before injection. From the results in Table IV, it appears that the haemolytic
agent contained in the tumour extract may be partly or wholly inactivated by
prior incubation with the antiserum. These findings suggest that circulating anti-
bodies against the haemolytic agent are present, at least during the later stages
of tumour growth. However, since it is necessary to dilute the tumour extract by
a factor of 10or 100to produce a clear demonstration ofneutralization, it islikely
that the titre ofantibody inthe serum is low.
DISCUSSION
Some of the features of the anaemia induced by implantation of the tumour
R2426 suggest that it might be attributable to a mechanism similar to that which
induces ac'quired haemolytic anaemias of the auto-immune type (Belcher, 1958,
1959). However, later findings (Belcher and Simpson, 1960), and the results
described in the present paper are incompatible with this explanation. There are
now good grounds for believing that the agent inducing the haemolytic episode
in rate bearing this tumour is infectious and multiplies within the host. The chief
evidence for this lies inthe observations that the agent responsible forthe anaemia
may be transferred to the recipient in a minute quantity of blood, that its con-
centration in the circulating blood ofthe host increases from the time ofimplant-
ation and that it may be passaged through a series of hosts without apparent
decline in virulence. Further investigations of the properties of the haemolytic
agent reveal that it is not filterable, is heat labile and is stable in ether, all findings
which suggest that the agent may be a virus (Mackie and McCartney, 1953).
Several other workers have described the multiplication of virus in tumour tissue
without aetiological relationship to it. Taylor and MacDowall (1949), Law and
Dunn (1951), Riley, Lilley, Heurto and Bardell (1960) and Haas (1960) have all
reported virus of various pathogenicity, found in mouse tumours, which may
be transplanted along with the tumour.
Ifthe conclusion that the virus-like agent is involved in the production ofthe
haemolytic episode is accepted, three possible modes of action of the agent may
be postulated.
1. The virus could alter the red cell surface in such a way that the cell became
susceptible to haemagglutination, haemolysis or premature destruction in the
reticulo-endothelial system.
2. Virus adsorbed to the red cell surface could bind antiviral antibodies ren-
dering the cell susceptible to destruction by any of the above mechanisms.
3. Combination of the virus with the cell surface could render it antigenic.
As a result, auto-antibodies could be produced against it.
It is not possible to state categorically which of these explanations is correct,
but there are some indications ofwhich is the most probable. Although the results
of the neutralization tests suggest that antiviral antibodies are developed, it is
improbable that the haemolytic episode is related to their development. The
shortest time between a transfusion of blood and the onset of the haemolytic
episode is two days and the longest 14 days. It is unlikely that antibody produc-
tion would come into plav in as short a time as 2 days, nor would the rate of
production of antibody to the virus be dependent on the amount of virus ori-
ginally injected. The same objections hold against the hypothesis that the virus
changes the red cell surface in such a way that it becomes antigenic. The sugges-
368RED CELL DESTRUCTION IN RATS 369
tion that the haemolytic anaemia may develop as a direct result of the virus is a
novel one and may not be substantiated on the basis of the present results. It
should be noted, however, that a similar mechanism has been postulated as being
responsible for the genesis of several cases of haemolytic anaemia of unknown
cause, in patients from whose blood several strains of haemaaglutinating virus,
notably Newcastle Disease Virus, have been isolated (Moolten and Clark, 1952;
Moolten, Clark, Glasser, Katz and Miller, 1953).
In the light of the findings described in this paper and a previous communi-
cation (Belcher and Simpson, 1960), it is possible to describe the development of
acute haemolytic anaemia in rats bearing the R2426 tumour in the following
terms. The R2426 tumour is the site ofmultiplication of an organism with virus-
like properties. Following implantation of the tumour into August rats, this
organism is released into the circulation and becomes attached to circulating red
cells. A point is reached when the number of particles attached to each cell
becomes sufficient to cause widespread lysis or agglutination as a result of which
there is a sharp fall in blood haemoglobin. Recoveryfrom the haemolytic episode
occurs partly as a result of compensating erythropoesis and partly because the
circulating red cells become desensitized to the action of the haemolytic agent.
The latter effect maypossiblybe due toblocking ofthered cellsurfacebyantiviral
antibodies or to the operation of a mechanism which destroys the virus receptor
sites on the cell surface. Antibodies to the virus are demonstrable in serum after
the haemolytic episode and these may act to keep the virus at the low level. If
the tumour is transplanted or blood from a tumour-bearing rat is transfused to a
normal recipient, the virus is free of constraint, able to multiply again, and in due
course to provoke a haemolytic episode in the recipient.
SUMMARY
Further investigations of the acute haemolytic anaemia developing in rats of
the " August " strain bearing the transplantable tumour R2426 are described. A
haemolytic episode could be induced in normal " August " rats by the transfusion
of a minute quantity ofblood from a recipient bearing the tumour R2426 and the
haemolytic agent could be passaged in this way through a series of hosts without
apparent deline in virulence. These and other observations suggest that the
responsible agent may be a viral infection associated in some way with the
tumour. The agent could be demonstrated in a number of tissues of infected
" August " rats but failed to maintain itself in the tissues of rats of two strains.
Thesameorasimilaragent was showntobeassociatedwith asecondtransplantable
tumour of the " August " strain, the tumour D266. Circulating antibodies to the
agent could be demonstrated in serum ofrats bearing the tumour R2426 following
their haemolytic episode. The haemolytic action of the agent is discussed in the
light of these findings.
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